76results about "Pancreas cancer vaccine" patented technology

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

Provided are methods for the administration of therapeutic bispecific anti-IGF-1R and anti-ErbB3 antibodies, either alone or in combination with other anti-cancer therapeutics.

The invention provides a chimeric antigen receptor (CAR) targeting NKG2D. Amino acid sequences of the CAR targeting NKG2D comprises the amino acid sequences of a single-chain antibody targeting NKG2D,an extracellular hinge region, a transmembrane region and an intracellular signal region which are sequentially connected from an amino terminal to a carboxyl terminal, respectively. The single-chainantibody targeting NKG2D comprises the amino acid sequences shown in SEQ ID NO: 1. The invention also provides a chimeric antigen receptor T-cell (CAR-T) targeting NKG2D and a preparation method thereof, as well as application of the CAR targeting NKG2D and the CAR-T targeting NKG2D in the prevention, diagnosis and treatment of liver cancer, cervical cancer, pancreatic cancer and other malignanttumors.

A specific chimeric antigen receptor targeting NKG2DL, its coding sequence, and modified immune response cells, as well as their preparation method and application. The modified immune response cells can effectively target and attack various tumor cells, especially positive tumor cells expressing NKG2DL, and can be used to prepare preparations for treating tumors.

The invention discloses an OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapy vector. The vector comprises lentivirus framework plasmid, a human EF1alpha promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody; the OCTS chimeric receptor structural domain comprises CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO. 17), an MESOTHELIN single-chain antibody light chain VL (SEQ ID NO. 18), an MESOTHELIN single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody inner linker Inner-Linker (SEQ ID NO. 20), a single-chain antibody inter-linker Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor linker (SEQ ID NO. 22), a CD8Transmembrane chimeric receptor transmembrane domain (SEQ ID NO. 23), a TCR chimeric receptor T-cell activation domain (SEQ ID NO. 26), and a chimeric receptor inducible co-stimulater area. In addition, the invention also discloses a construction method of the vector as well as application of the vector to preparation of medicines for treating pancreatic cancer and malignant mesothelioma.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

The invention provides a carrier assembly carrying a gene element combination, a recipient cell library, a preparation and screening method and an application, the recipient cell library is formed byfusing cells and the carrier assembly, and the carrier assembly at least carries three gene elements, respectively a plurality of first gene elements encoding one or more idiotypic synNotch receptors,respectively; a second gene element carrying one or more gene loops; a third gene element encoding one or more idiotypic chimeric antigen receptors. Wherein, when the first genetic element encodes one idiotypic synNotch receptor, the third genetic element must encode at least three idiotypic chimeric antigen receptors, and when the third genetic element encodes one idiotypic chimeric antigen receptor, the first genetic element must encode three idiotypic synNotch receptors. The gene loop is pre-programmed, a regulatory homeopathic factor is combined with a transcription factor, upon activation of the synNotch receptor encoded by the first gene element, the chimeric antigen receptor encoded by the third gene element is controllably expressed.

Described herein is a combination therapy suited to the treatment of pancreatic cancer and the like. Also described is a method of potentiating the therapeutic effect of chemotherapeutic agents such as gemcitabine.

The invention relates to the field of biological medicines, in particular to a single-chain antibody specifically bound with CLDN18.2 and a chimeric antigen receptor (CAR) containing the single-chain antibody. The invention also relates to reconstructed immune cells expressing the CAR, or co-expressing the CAR and a further bioactive molecule (e.g., a PD-1 antibody or mIL-15), nucleic acid molecules encoding such CAR or co-expressed molecules, and methods of preparing the reconstructed immune cells. The invention also relates to application of the CAR and the immune cells in preventing and / or treating cancers such as gastric cancer, gastric adenocarcinoma and pancreatic cancer and a method for preventing and / or treating the cancers such as the gastric cancer, the gastric adenocarcinoma and the pancreatic cancer.

The invention discloses a double-targeting chimeric antigen receptor, which comprises a double-antigen binding region, a first hinge region, a chimeric antigen receptor T cell activation domain and a protein co-expression self-cleavage domain which are sequentially connected in series, and the double-antigen binding region comprises a heavy chain VH and a light chain VL of an MSLN and MUC1 single-chain antibody which are connected in series, and a second hinge region connected with the MSLN and the MUC1 single-chain antibody. The double-targeting CAR-T cell can kill tumor cells expressing double antigens, killing is more accurate and efficient, meanwhile, the off-target effect is reduced or avoided, the side effect of non-specific killing is reduced, and the anti-tumor effect is enhanced.

The invention discloses a double-chimeric antigen receptor, a T cell and a construction method and an application thereof, which belong to the field of cellular immunotherapy of tumors. The inventionspecifically relates to a specific structure and a construction method of the double chimeric antigen receptor T cell (dCAR-T cell), and preliminarily discusses the in-vivo and in-vitro activity of the dCAR-T cell. The selected tumor-associated antigens are mesothelin and carcino-embryonic antigens, and researches show that the two tumor antigens can be simultaneously expressed on the surface of asolid tumor, such as pancreatic cancer. The invention discloses an antigen receptor. The in-vitro and in-vivo tests prove that the constructed dCAR-T cell can be permanently and effectively activatedonly under the condition that two antigens are simultaneously recognized, and has efficient anti-tumor activity, so that a specific tumor killing function can be exerted, and the application of CAR-Tcell immunotherapy is improved.

The invention discloses an ROBO1 CAR-NK cell carrying a suicide gene as well as a preparation method and application of the ROBO1 CAR-NK cell. In order to improve the safety and controllability of theCAR-NK therapy, a suicide gene switch element is integrated into a genome through a lentiviral transfection technology on the basis of the current ROBO1 CAR-NK cell to form the CAR-NK with the suicide gene. By adding the suicide gene, the CAR-NK cells can be better controlled, and the clinical safety is further improved.

The invention discloses a humanized antibody and application thereof, the humanized antibody comprises a heavy chain variable region and a light chain variable region, and can specifically target a CH1 structural domain 162 site sialylated epitope of IgG, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 2. The humanized antibody can effectively inhibit the growth, invasion and suspension growth ability of tumor cells, has an obvious anti-tumor effect, and also can inhibit the activation of a c-Met / Wnt signal channel and an FAK signal channel of the tumor cells.

The invention relates to a universal chimeric antigen receptor T cell targeting claudin 18.2, a construction method and an application of the universal chimeric antigen receptor T cell, and belongs tothe technical field of molecular biomedicine. The invention provides a single-chain antibody targeting the claudin 18.2, and the chimeric antigen receptor T cell containing the single-chain antibodytargeting the claudin 18.2. The chimeric antigen receptor targeting the claudin 18.2 can specifically target the claudin 18.2, promote the amplification of the T cell in the body of a patient, efficiently and specifically kill tumor cells, and hardly cause damage to normal cells.

The present disclosure provides methods for expanding TIL populations from fine needle aspirates (FN As) or small biopsies which contain low numbers of TILs, using the methods disclosed herein including in a closed system that leads to improved phenotype and increased metabolic health of the TILs in a shorter time period.

The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.

The purpose of this invention is to provide an immunocompetent cell that targets mesothelin. Another purpose is to produce an immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin-7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19). It is preferable that: the cell surface molecule that specifically recognizes human mesothelin is a chimera antigen receptor (CAR) provided with a single-chain antibody, a membrane-spanning domain and a signal transmission domain which induces the activation of the immunocompetent cell; and that the heavy chain variable domain and the light chain variable domain are linked via a peptide linker comprising a sequence of 2-30 amino acids.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Described are methods for treating or preventing cancer in a subject by administering a vaccine, an inhibitor of idoleamine 2,3-dioxygenase to the subject. The vaccine may comprise and allogenic PDA tumor cell engineered to secrete granulocyte macrophages colony-stimulating factor (GM-CSF).

Attenuated Toxoplasma gondii mutants and methods using the same as vaccines in the prevention or treatment pancreatic cancer are provided.

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

The invention provides a chimeric antigen receptor cell library carrying a gene element combination, preparation and screening methods and application. The chimeric antigen receptor cell library is formed by fusion of cells and a carrier assembly, the carrier assembly carries three gene elements, and the three gene elements are respectively as follows: a plurality of first gene elements for encoding one or more unique chimeric antigen receptors; a second genetic element carrying one or more genetic loops; and a third genetic element encoding one or more inducible proteins. The genetic loop ispreprogrammed and is a combination of a regulatory homeopathic factor and a transcription factor; and the inducible protein comprises one or two of drug resistance protein and suicide protein. By designing the chimeric antigen receptor library-genetic loop-inducible protein coupling scheme, the cell library and screening of complex and unknown disease target antigens are realized, so that the problems that antigens in abnormal antigen expression diseases are complex, diverse and easy to change, target identification is difficult and the like are solved. The method has a wide application prospect.

The application is directed a method of treating a cancer in subject by administering to the subject a therapeutically effective amount of polymorphonuclear leukocytes genetically modified to express a recombinant chimeric antigen receptor (CAR) or T cell receptor (TCR). Further provided are modified polymorphonuclear leukocytes and related compositions for use in such methods.

The invention discloses a synergistic and depletion-resistant chimeric antigen receptor T cell and application thereof in preparation of a medicine for treating tumors. The synergistic and depletion-resistant chimeric antigen receptor T cell comprises an antigen binding structural domain (scFv) and a signal transduction structural domain, wherein the signal transduction structural domain comprises a first transduction structural domain and a second transduction structural domain, and the antigen binding structural domain is connected in series between the first transduction structural domain and the second transduction structural domain; the first conduction structural domain comprises a receptor signal structural domain and / or a costimulatory structural domain; the second conductive domain comprises a transmembrane structural domain DAP12, and the transmembrane structural domain DAP12 is or is not linked to the costimulatory structural domain and / or an elementary signal domain. According to the T cell expressing the chimeric antigen receptor, the chimeric antigen receptor can be more efficiently and stably expressed in the T cell, so that a killing effect on a target cell can be better played, the durability of CAR-T is improved, the expression of a depletion marker is lower, and the memory type T cell is richer.